| 57.67 -1.59 (-2.68%) | 11-12 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 71.91 | 1-year : | 78.16 |
| Resists | First : | 61.56 | Second : | 66.91 |
| Pivot price | 59.38 |
|||
| Supports | First : | 52.9 | Second : | 44.02 |
| MAs | MA(5) : | 57.19  |
MA(20) : | 59.38 |
| MA(100) : | 40.76 |
MA(250) : | 23.64 |
|
| MACD | MACD : | 0.5 |
Signal : | 1.2 |
| %K %D | K(14,3) : | 35.2 |
D(3) : | 28.9 |
| RSI | RSI(14): 50.2 |
|||
| 52-week | High : | 66.91 | Low : | 0.66 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ NKTR ] has closed above bottom band by 36.3%. Bollinger Bands are 15.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 59.23 - 59.53 | 59.53 - 59.72 |
| Low: | 55.55 - 55.94 | 55.94 - 56.19 |
| Close: | 57.1 - 57.7 | 57.7 - 58.08 |
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.
Wed, 12 Nov 2025
Wall Street Analysts Are Neutral on Top Healthcare Picks - The Globe and Mail
Wed, 12 Nov 2025
Nektar Therapeutics: Balancing The Immune System To Potential Blockbuster Markets - Seeking Alpha
Wed, 12 Nov 2025
Nektar Therapeutics: Cautiously Positive Moving Into Phase 2b Readout - Seeking Alpha
Mon, 10 Nov 2025
Nektar Therapeutics Reveals Promising Phase 2b Trial Results - TipRanks
Mon, 10 Nov 2025
Oppenheimer maintains Outperform rating on Nektar Therapeutics stock By Investing.com - Investing.com Nigeria
Sun, 09 Nov 2025
Assessing Nektar Therapeutics (NKTR) Valuation After Recent Surge in Share Price - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 19 (M) |
| Shares Float | 18 (M) |
| Held by Insiders | 0.7 (%) |
| Held by Institutions | 48.7 (%) |
| Shares Short | 1,730 (K) |
| Shares Short P.Month | 1,610 (K) |
| EPS | -8.65 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -1.95 |
| Profit Margin | -163.2 % |
| Operating Margin | -320.3 % |
| Return on Assets (ttm) | -31.6 % |
| Return on Equity (ttm) | -440.8 % |
| Qtrly Rev. Growth | -52.5 % |
| Gross Profit (p.s.) | 3.28 |
| Sales Per Share | 3.93 |
| EBITDA (p.s.) | -7.22 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -185 (M) |
| Levered Free Cash Flow | -58 (M) |
| PE Ratio | -6.68 |
| PEG Ratio | 0 |
| Price to Book value | -29.73 |
| Price to Sales | 14.63 |
| Price to Cash Flow | -5.94 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|